Delaney Dennis R Has $1.34 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Delaney Dennis R boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 131.4% during the 2nd quarter, Holdings Channel reports. The fund owned 2,865 shares of the pharmaceutical company’s stock after buying an additional 1,627 shares during the period. Delaney Dennis R’s holdings in Vertex Pharmaceuticals were worth $1,343,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital World Investors lifted its position in shares of Vertex Pharmaceuticals by 21.3% during the fourth quarter. Capital World Investors now owns 21,805,770 shares of the pharmaceutical company’s stock valued at $8,872,586,000 after purchasing an additional 3,824,103 shares in the last quarter. Capital Research Global Investors increased its stake in Vertex Pharmaceuticals by 61.0% in the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company’s stock valued at $2,401,000,000 after buying an additional 2,176,218 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Vertex Pharmaceuticals by 21.2% during the 1st quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company’s stock worth $1,999,080,000 after buying an additional 837,461 shares in the last quarter. Swedbank AB purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $277,317,000. Finally, AMF Tjanstepension AB bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $257,655,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of several research analyst reports. Guggenheim boosted their price objective on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Canaccord Genuity Group increased their target price on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a research report on Wednesday, July 31st. HC Wainwright increased their price objective on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the company a “buy” rating in a report on Monday, August 5th. StockNews.com lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 5th. Finally, Redburn Atlantic began coverage on shares of Vertex Pharmaceuticals in a report on Thursday, June 27th. They set a “buy” rating and a $545.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $485.91.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Sangeeta N. Bhatia sold 646 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the transaction, the director now owns 4,435 shares in the company, valued at $2,217,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the sale, the chief marketing officer now owns 30,099 shares in the company, valued at approximately $14,198,300.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,047 shares of company stock valued at $16,843,806. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ VRTX opened at $474.16 on Thursday. Vertex Pharmaceuticals Incorporated has a one year low of $341.85 and a one year high of $510.64. The stock has a market capitalization of $122.38 billion, a P/E ratio of 30.77 and a beta of 0.40. The firm’s 50 day simple moving average is $483.42 and its two-hundred day simple moving average is $451.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm earned $3.53 earnings per share. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.